Peanut Allergen Threshold Study (PATS): validation of eliciting doses using a novel single-dose challenge protocol
View/ Open
Author
Zurzolo, Giovanni A
Allen, Katrina J
Taylor, Steve L
Baumert, Joseph L
Tang, Mimi L K
Gurrin, Lyle C
Mathai, Michael L
Nordlee, Julie A
DunnGalvin, Audrey
Hourihane, Jonathan O’B
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1186/1710-1492-9-35Metadata
Show full item recordCitation
Zurzolo, G. A., K. J. Allen, S. L. Taylor, W. G. Shreffler, J. L. Baumert, M. L. K. Tang, L. C. Gurrin, et al. 2013. “Peanut Allergen Threshold Study (PATS): validation of eliciting doses using a novel single-dose challenge protocol.” Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology 9 (1): 35. doi:10.1186/1710-1492-9-35. http://dx.doi.org/10.1186/1710-1492-9-35.Abstract
Background: The eliciting dose (ED) for a peanut allergic reaction in 5% of the peanut allergic population, the ED05, is 1.5 mg of peanut protein. This ED05 was derived from oral food challenges (OFC) that use graded, incremental doses administered at fixed time intervals. Individual patients’ threshold doses were used to generate population dose-distribution curves using probability distributions from which the ED05 was then determined. It is important to clinically validate that this dose is predictive of the allergenic response in a further unselected group of peanut-allergic individuals. Methods/Aims This is a multi-centre study involving three national level referral and teaching centres. (Cork University Hospital, Ireland, Royal Children’s Hospital Melbourne, Australia and Massachusetts General Hospital, Boston, U.S.A.) The study is now in process and will continue to run until all centres have recruited 125 participates in each respective centre. A total of 375 participants, aged 1–18 years will be recruited during routine Allergy appointments in the centres. The aim is to assess the precision of the predicted ED05 using a single dose (6 mg peanut = 1.5 mg of peanut protein) in the form of a cookie. Validated Food Allergy related Quality of Life Questionnaires-(FAQLQ) will be self-administered prior to OFC and 1 month after challenge to assess the impact of a single dose OFC on FAQL. Serological and cell based in vitro studies will be performed. Conclusion: The validation of the ED05 threshold for allergic reactions in peanut allergic subjects has potential value for public health measures. The single dose OFC, based upon the statistical dose-distribution analysis of past challenge trials, promises an efficient approach to identify the most highly sensitive patients within any given food-allergic population.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850217/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879306
Collections
- HMS Scholarly Articles [17928]
Contact administrator regarding this item (to report mistakes or request changes)